Page 5 - Latest Updates on Diabetes
Obesity injections may have less weight loss effect in reality: Study
The study, published in the Obesity Journal, examined the effects of anti-obesity injectables on weight reduction and blood sugar regulation (glycaemic control) in a real-world setting
 "Obesity injections may have less weight loss effect in reality: Study")
Eli Lilly's weight loss drug Mounjaro sales bulk up 60% on dosage upgrade
It logged value sales worth Rs 12.61 crore in May, compared to Rs 7.88 crore in April.
 "Eli Lilly's weight loss drug Mounjaro sales bulk up 60% on dosage upgrade")
Lilly's obesity drug Mounjaro's sales rise 60% in India amid rising demand
The US drugmaker sold ₹12.6 crore ($1.5 million) worth of the injections last month, according to market analysis firm Pharmarack Technologies
Biocon gets CDSCO approval for generic diabetes medication 'Liraglutide'
The approval is for the generic version of Victoza, indicated for the treatment of insufficiently controlled Type 2 Diabetes Mellitus in adults, adolescents and children aged 10 years and above
 "Biocon gets CDSCO approval for generic diabetes medication 'Liraglutide'")
Novo Nordisk to launch weight-loss drug Wegovy in India ahead of schedule
Amid rising demand and Eli Lilly's Mounjaro launch, Novo Nordisk is advancing plans to introduce its obesity drug Wegovy in the Indian market
 "Novo Nordisk to launch weight-loss drug Wegovy in India ahead of schedule")
Can the '2 per 20' rule really help stabilise blood sugar without exercise?
Research shows that light walking for 2 minutes after every 20 minutes of sitting may significantly lower post-meal blood sugar levels
 "Can the '2 per 20' rule really help stabilise blood sugar without exercise?")
5 products to be launched in 18 mths, US insulin mkt share up: BBL MD & CEO
Achieving 15 per cent year-on-year growth, with nearly four biosimilars with $200 million in revenue, is a big feat, says Tambe
 "5 products to be launched in 18 mths, US insulin mkt share up: BBL MD & CEO")
Insulin's century-old legacy still stands tall amid new diabetes drugs
Despite the rise of GLP-1s and oral therapies, insulin remains vital for millions, particularly those with type 1 diabetes and other insulin-dependent conditions
 "Insulin's century-old legacy still stands tall amid new diabetes drugs")
Patent loss led to rise in prescriptions of new generation diabetes drugs
Experts say 85% price drop in empagliflozin expected to boost SGLT2 usage; SGLT-2 class of drugs account for 25-30% of all diabetes prescriptions
 "Patent loss led to rise in prescriptions of new generation diabetes drugs")
What is Type 5 diabetes? IDF recognises malnutrition-linked condition
Long overlooked and often misdiagnosed, Type 5 diabetes, caused by malnutrition-linked reduced insulin production, has finally gained official recognition
 "What is Type 5 diabetes? IDF recognises malnutrition-linked condition")
Hit the gym! Building muscles may cut diabetes risk by 44%, genes no bar
Muscle up, sugar down: A new study has found individuals with high muscle strength have a 44% lower risk of developing type 2 diabetes, irrespective of their genetic predisposition to the disease
 "Hit the gym! Building muscles may cut diabetes risk by 44%, genes no bar")
Eli Lilly launches blockbuster anti-obesity drug Mounjaro in India. Prices here
Eli Lilly's much-anticipated drug for diabetes and obesity, that competes with Ozempic globally, is now in India. Here's what you need to know
Glenmark launches Empagliflozin for diabetes in India under Glempa brand
The medications are designed to improve glycemic control in adults with type 2 diabetes mellitus while also reducing cardiovascular outcomes in patients with cardiovascular risk
 "Glenmark launches Empagliflozin for diabetes in India under Glempa brand")
Biocon launches drug Liraglutide for diabetes, Biolide for obesity in UK
Launch comes after approval from the Medicines and Healthcare Products Regulatory Agency (MHRA), UK, earlier this year, making Biocon the first generics company to obtain approval for gLiraglutide
 "Biocon launches drug Liraglutide for diabetes, Biolide for obesity in UK")
Asian healthcare market to touch $5 trillion by 2030, says BCG report
The pharmaceutical and MedTech sectors are also expected to see significant growth of 9 per cent and 8 per cent, respectively, over the next five years
 "Asian healthcare market to touch $5 trillion by 2030, says BCG report")
Lupin acquires Huminsulin from Lilly to strengthen diabetes portfolio
The Huminsulin range is vital for managing both type 1 and type 2 diabetes, helping control blood sugar levels in adults and children
 "Lupin acquires Huminsulin from Lilly to strengthen diabetes portfolio")
88 mn women screened for cervical cancer under national programme: Govt
Under the same programme, over 14 crore were screened for breast cancer and more than 26 crore for oral cancer
 "88 mn women screened for cervical cancer under national programme: Govt")
ICMR sets up India's first diabetes biobank in Chennai for research
Biobanks are critical in biomedical research, collecting, processing, storing and distributing biospecimens to support scientific research, the article said
 "ICMR sets up India's first diabetes biobank in Chennai for research")
India's health at a sugar tipping point, 50% see glucose imbalance
According to a report by diagnostic service provider Thyrocare, 49.43 per cent of the tested population in India exhibited abnormal blood glucose levels
 "India's health at a sugar tipping point, 50% see glucose imbalance")
Biocon Biologics, Diabetes Africa collab over nurses project in Ethiopia
Ethiopia, with a 2-3 per cent diabetes prevalence rate, ranks among the top four countries in sub-Saharan Africa for adult diabetes cases
 "Biocon Biologics, Diabetes Africa collab over nurses project in Ethiopia")